A Study of T-DXd as Monotherapy or in Combination with Anti-cancer Agents in Patients with Selected HER2-expressing Tumors

Trial Identifier: D781AC00001
Sponsor: AstraZeneca
Collaborator:
Daiichi Sankyo Co., Ltd.
Start Date: February 2024
Primary Completion Date: October 2025
Study Completion Date: April 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN beijing, CN, 100191
CN Beijing, CN, 100142
CN Changchun, CN, 130021
CN Changsha, CN, 410013
CN Chengdu, CN, 610041
CN Chongqing, CN, 400030
CN Dongyang, CN, 322100
CN Guangzhou, CN, 510145
CN Guangzhou, CN, 510630
CN Hangzhou, CN, 310022
CN Hangzhou, CN, 310003
CN Hangzhou, CN, 310016
CN Harbin, CN, 150081
CN Hefei, CN, 230031
CN Kunming, CN, 650118
CN Lishui, CN, 323000
CN nanchang, CN, 330029
CN Shandong, CN
CN shanghai, CN, 200011
CN Shanghai, CN, 200032
CN Shanghai, CN, 200001
CN Shenyang, CN, 110016
CN Taiyuan, CN, 030001
CN Wuhan, CN, 430022
CN Xian, CN, 710061
CN Xuzhou, CN, 221009
CN Yinchuan, CN, 750004
CN zhengzhou, CN, 450002
CN Zhengzhou, CN, 450008